CORRESP Filing
Silexion Therapeutics Corp
Date: Sept. 2, 2025 · CIK: 0002022416 · Accession: 0001178913-25-003198
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289860
Letter
VIA EDGAR Attention: Division of Corporation Finance, Daniel Crawford Silexion Therapeutics Corp Registration Statement on Form S-1 Filed August 26, 2025 SEC File Number 333-289860
Re:
Dear Mr. Crawford:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will become effective at 9:00 a.m. Eastern Time on Thursday, September 4, 2025, or as soon as practicable thereafter.
Please contact Jonathan M. Nathan, Adv., at Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify him when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Hadar
Show Raw Text
CORRESP 1 filename1.htm Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Telephone: +972-3-756499 September 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance, Daniel Crawford Re: Silexion Therapeutics Corp Registration Statement on Form S-1 Filed August 26, 2025 SEC File Number 333-289860 Dear Mr. Crawford: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will become effective at 9:00 a.m. Eastern Time on Thursday, September 4, 2025, or as soon as practicable thereafter. Please contact Jonathan M. Nathan, Adv., at Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify him when this request for acceleration has been granted. Sincerely, /s/ Ilan Hadar Ilan Hadar Chief Executive Officer CC: Daniel Crawford Securities and Exchange Commission Mirit Horenshtein Hadar Silexion Therapeutics Corp Gary Emmanuel, Esq. Greenberg Traurig, LLP Jonathan M. Nathan, Adv. Meitar Law Offices